Fujian Haixi Pharma Delays Hong Kong Trading Debut Pending Regulatory Approval

MT Newswires Live

Oct 17

Fujian Haixi Pharmaceuticals (HKG:2637) said its Hong Kong initial public offering timetable has been delayed as the company needs more time to finalize its listing announcement and secure regulatory clearance, according to a late-Thursday bourse filing.

The company was originally scheduled to release its allocation results on Thursday, ahead of its planned trading debut on the Hong Kong Stock Exchange on Friday.

Fujian Haixi said the revised listing timetable will be announced as soon as practicable once regulatory clearance is secured.

The announcement was expected to include details on the final offer price, subscription levels in the Hong Kong public offering and international placing, and the basis of share allocation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2576035807"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576035807\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576035807?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576035807","market":"fut","top_or_hot":-1,"title":"Fujian Haixi Pharma Delays Hong Kong Trading Debut Pending Regulatory Approval","media":"MT Newswires Live","content":"<html><body><p> Fujian Haixi Pharmaceuticals (HKG:2637) said its Hong Kong initial public offering timetable has been delayed as the company needs more time to finalize its listing announcement and secure regulatory clearance, according to a late-Thursday bourse filing.</p><p>The company was originally scheduled to release its allocation results on Thursday, ahead of its planned trading debut on the Hong Kong Stock Exchange on Friday.</p><p>Fujian Haixi said the revised listing timetable will be announced as soon as practicable once regulatory clearance is secured.</p><p>The announcement was expected to include details on the final offer price, subscription levels in the Hong Kong public offering and international placing, and the basis of share allocation.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fujian Haixi Pharma Delays Hong Kong Trading Debut Pending Regulatory Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFujian Haixi Pharma Delays Hong Kong Trading Debut Pending Regulatory Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-17 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Fujian Haixi Pharmaceuticals (HKG:2637) said its Hong Kong initial public offering timetable has been delayed as the company needs more time to finalize its listing announcement and secure regulatory clearance, according to a late-Thursday bourse filing.</p><p>The company was originally scheduled to release its allocation results on Thursday, ahead of its planned trading debut on the Hong Kong Stock Exchange on Friday.</p><p>Fujian Haixi said the revised listing timetable will be announced as soon as practicable once regulatory clearance is secured.</p><p>The announcement was expected to include details on the final offer price, subscription levels in the Hong Kong public offering and international placing, and the basis of share allocation.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2576035807","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576035807","pubTimestamp":1760663811,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Fujian Haixi Pharmaceuticals  said its Hong Kong initial public offering timetable has been delayed as the company needs more time to finalize its listing announcement and secure regulatory clearance, according to a late-Thursday bourse filing.The company was originally scheduled to release its allocation results on Thursday, ahead of its planned trading debut on the Hong Kong Stock Exchange on Friday.Fujian Haixi said the revised listing timetable will be announced as soon as practicable once regulatory clearance is secured.The announcement was expected to include details on the final offer price, subscription levels in the Hong Kong public offering and international placing, and the basis of share allocation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"福建海西药业推迟香港上市等待监管机构批准","themeId":"66a4019331b03d4321cdeb149dbc6c5b","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":0.9},"content_text":"Fujian Haixi Pharmaceuticals (HKG:2637) said its Hong Kong initial public offering timetable has been delayed as the company needs more time to finalize its listing announcement and secure regulatory clearance, according to a late-Thursday bourse filing.The company was originally scheduled to release its allocation results on Thursday, ahead of its planned trading debut on the Hong Kong Stock Exchange on Friday.Fujian Haixi said the revised listing timetable will be announced as soon as practicable once regulatory clearance is secured.The announcement was expected to include details on the final offer price, subscription levels in the Hong Kong public offering and international placing, and the basis of share allocation.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}